

Effect of phosphoramidon on big endothelin-2 conversion into endothelin-2 in human renal adenocarcinoma (ACHN) cells

Analysis of endothelin-2 biosynthetic pathway

Kazuyuki Yorimitsu^a, Osamu Shinmi^{b,c}, Mariko Nishiyama^b, Kayoko Moroi^b, Yoshiki Sugita^c,
Toshihiro Saito^a, Yoshiaki Inagaki^a, Tomoh Masaki^d and Sadao Kimura^a

^aThe Third Department of Internal Medicine and ^bCenter for Neurobiology and Molecular Immunology, School of Medicine, Chiba University, Chiba 260, Japan, ^cDepartment of Biochemistry, Institute of Basic Medical Sciences, Tsukuba University, Tsukuba 305, Japan and ^dDepartment of Pharmacology, Kyoto University School of Medicine, Kyoto 606, Japan

Received 21 October 1992.

The biosynthetic pathway of endothelin (ET)-2 was analyzed in cultured ACHN cells. In the supernatant, we detected three ET-2-related peptides, ET-2, big ET-2(1–38) and big ET-2(22–38). Phosphoramidon decreased the amount of ET-2 and increased that of big ET-2(1–38) dose-dependently. The amount of big ET-2(1–37) did not significantly change. These results suggest that big ET-2 is composed of 38 and not 37 amino acid residues, and that a putative ET-2-converting enzyme (ECE-2) should be classified as a phosphoramidon-sensitive neutral metalloprotease, bearing a resemblance to the putative ET-1-converting enzyme (ECE-1) in endothelial cells.

Endothelin-2; Big endothelin-2; Endothelin-converting enzyme; Phosphoramidon; Human renal adenocarcinoma (ACHN) cell

1. INTRODUCTION

Endothelin-2 (ET-2), originally predicted from its nucleotide sequence, belongs to the endothelin peptide family [1–3]. Pharmacological studies revealed that ET-2 has similar biological activities, including vasoconstrictor activity, to ET-1, although its physiological roles are not thoroughly clarified [4]. Later, massive production of ET-2 by ACHN, a human renal adenocarcinoma cell line, was pointed out by isolation, amino acid sequence analysis and Northern blot analysis [5,6]. With respect to the biosynthetic pathway of ET-1, we have proposed that ET-1 is produced from a 39 (porcine) or 38 (human) intermediate form, big ET-1, through unusual proteolytic cleavage at Trp²¹-Val²² by an ET-converting enzyme (ECE) [1,2]. The biosynthetic pathway was confirmed by finding of the related peptides, ET-1, big ET-1(1–39) and big ET-1(22–39) in the

culture supernatant [7]. We have shown that the physiological importance of the conversion of big ET-1 is to increase the vasoconstrictor activity by 140-fold on cleavage to ET-1 [8]. Furthermore, we and others have shown that the intracellular conversion from big ET-1 to ET-1 in endothelial cells is markedly inhibited by a metalloprotease inhibitor, phosphoramidon, suggesting that ET-1-converting enzyme (ECE-1) is a phosphoramidon-sensitive neutral metalloprotease [9,10].

In contrast to ET-1, the native biosynthetic pathway of ET-2 in ET-2-producing cells has not been reported yet, although Kosaka et al. analyzed the biosynthetic pathway using CHO-K1 cells transfected with an expression vector containing human prepro-ET-2 cDNA [11]. They suggested that ET-2 is produced from big ET-2(1–38) and not from big ET-2(1–37), although the latter has been proposed as the intermediate form from the nucleotide sequence of cDNA encoding ET-2 [5]. Therefore, we conducted our study to clarify the native biosynthetic pathway of ET-2 and the phosphoramidon sensitivity of ET-2-converting enzyme (ECE-2) using ACHN cells. This is the first demonstration reporting the characteristic of ECE-2.

2. MATERIALS AND METHODS

2.1. Peptides and antisera

Human ET-1, ET-2, ET-3 and big ET-2(1–37) were obtained from Peptide Institute Inc. (Osaka, Japan). Human big ET-2(22–37) was obtained from Peninsula Laboratories Inc. (Belmont, CA). Human

Correspondence address: S. Kimura, Division of Functional Neurobiology, Center for Neurobiology and Molecular Immunology, School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba 260, Japan. Fax: (81) (43) 222-7853.

Abbreviations: ET, endothelin; ECE, endothelin-converting enzyme; Trp, tryptophan; Val, valine; As-ETC, anti-ET-2(15–21) antiserum; As-bET2C, anti-big ET-2(31–38) antiserum; As-ETL, anti-ET-2(1–21) antiserum; AcCN, acetonitrile; TFA, trifluoroacetic acid; HPLC, high performance liquid chromatography; RIA, radioimmunoassay; ir, immunoreactive.

big ET-2(1-38), big ET-2(22-38) and big ET-2(31-38) were synthesized by an automated peptide synthesizer (Applied Biosystems, Model 430A). Anti-ET-2(15-21) antiserum (As-ETC) was obtained from IBL (Tochigi, Japan). Anti-big ET-2(31-38) (As-bET2C) and anti-ET-2(1-21) (As-ETL) antisera were produced with a similar method reported previously [12]. Briefly, big ET-2(31-38) or ET-2(1-21) was conjugated with keyhole limpet hemocyanin using the glutaraldehyde coupling procedure. As-bET2C or As-ETL was obtained by immunizing New Zealand white rabbits 5 times with the conjugates every 2 weeks. ACHN, a human renal adenocarcinoma cell line, was obtained from American Type Culture Collection.

2.2. Analysis of culture supernatant

ACHN cells were cultured to confluence on 90 mm diam. dishes in minimum essential medium supplemented with Earle's salts, glutamic acid, non-essential amino acids (MEM, Gibco, Grand Island, NY), 10% fetal calf serum, penicillin G (100 U/ml), and streptomycin (100 µg/ml) at 37°C in a CO₂ incubator (95% air-5% CO₂). Then, the culture medium was changed to a serum-free medium and further incubated for 24 h. The supernatants were collected and loaded onto a Sep-Pak C18 cartridge (Waters, Milford, MA). ET-2-related peptides were eluted with 50% acetonitrile (AcCN) in 0.1% trifluoroacetic acid (TFA) and separated by a reverse-phase column (Cosmosil SC18-AR, 4.6 × 250 mm, Nacalai tesque, Kyoto, Japan) with a 37.5 min linear gradient of AcCN (12.5-50%) on 0.1% TFA at a flow rate of 1 ml/min at 40°C. Aliquots of fractions were assayed by radioimmunoassay (RIA) with three antisera (As-ETC, As-ETL, As-bET2C).

2.3. Effect of phosphoramidon on conversion from big ET-2 to ET-2

ACHN cells were cultured to confluence in 90 mm diam. dishes as described above. Then, the medium was changed to a serum-free medium with phosphoramidon (10⁻⁴, 10⁻⁵, 10⁻⁶, 10⁻⁷, and 10⁻⁸ M) and further incubated for 24 h. The supernatants from three dishes at each concentration were combined and loaded onto a Sep-Pak C18 cartridge and the eluates were separated on a reverse-phase column (Cosmosil SC18-AR, 4.6 × 250 mm) with the same conditions as described above. Aliquots of fractions were submitted to RIA with the three antisera.

2.4. RIAs for ET related peptides

RIAs were performed similarly as described previously [12]. ET-1 and big ET-2(22-38) were radioiodinated by the chloramin T method

and the monoiodinated peptides were purified by reverse-phase HPLC. Labeled ET-1 was used as a radioactive ligand for measuring ET-2 using cold ET-2 as standard. EC₅₀s of the antisera to ET-2-related peptides were as follows: EC₅₀s of As-bET2C to big ET-2(1-38) and big ET-2(22-38) were 295.3 and 198.0 fmol/tube, respectively; those of As-ETC to ET-1, ET-2, ET-3 were 310.3, 379.5, 255.7 fmol/tube, respectively; and those of As-ETL to ET-2, big ET-2(1-38), big ET-2(1-37) were 36.8, 66.2, 37.0 fmol/tube, respectively.

3. RESULTS AND DISCUSSION

3.1. Cross-reactivities of antisera

Typical standard curves for RIA with As-bET2C are shown in Fig. 1. As-bET2C recognized big ET-2(1-38) and big ET-2(22-38), but not big ET-2(1-37), big ET-2(22-37), ET-1, ET-2 and ET-3 (the cross-reactivity was less than 0.1%). The recognition site for As-ETL was considered to exist in the loop portion of ET-2, because As-ETL had almost equal EC₅₀ values for ET-2, big




Fig. 2. Analysis of ir-ET-2-related peptides in the culture supernatant of ACHN cells. The supernatant was separated by reverse-phase HPLC as described in section 2. Ir-ET-2-related peptides were monitored by As-ETL (a), As-ETC (b) and As-bET2C (c). Arrows indicate the elution positions of synthetic standards of big ET 2(22-38) (A), big ET-2(22-37) (B), big ET-2(1-38) (C), big ET-2(1-37) (D) and ET-2(1-21) (E).




Fig. 1. Typical standard curves of big ET-2(1-38) (●), big ET-2(1-37) (○), big ET-2(22-38) (□), big ET-2(22-37) (△), ET-1 (▲), ET-2 (△) and ET-3 (□) in the RIA with the antiserum As-bET2C.




Fig. 3. Dose dependence of the effects of phosphoramidon on big ET-2 conversion. ET-2(1-21) (●), big ET-2(1-38) (■), big ET-2(22-38) (○), big ET-2(1-37) (▲) and unknown (□).

ET-2(1-37) and big ET-2(1-38). As-ETC recognized the C-terminal Trp moiety of ET-1, ET-2 and ET-3, and cross-reacted with big ET-2(1-38), -(1-37), -(22-38) and -(22-37) less than 0.1% (data not shown).

3.2. ET-2 related peptides in culture supernatant of ACHN cells

Fig. 2 showed the elution pattern of immunoreactive (ir)-ET-2-related peptides after the HPLC. Two major ir-peaks (Fraction 58 and 29) and three minor ir-peaks (Fraction 52, 54 and 44) were detected. Except Fraction 44, the retention times of Fraction 58, 29, 52 and 54 corresponded to those of synthetic peptides, ET-2(1-21), big ET-2(22-38), big ET-2(1-38) and big ET-2(1-37), respectively, agreeing with the cross-reactivities of the three antisera mentioned above. As an example, Fraction 58 (ET-2) was recognized with As-ETL and As-ETC. No ir-peak could be seen with Fraction 58 with As-bET2C, because As-bET2C cross-reacted with ET-2 less than 0.1% (Fig. 1). ACHN cells produced almost equal quantities of big ET-2(22-38) and ET-2(1-21) simultaneously into the culture media. Fraction 44 did not correspond chromatographically to any one of the ET-2-related peptides mentioned above, and seemed to be a fragment of ET-2 or big ET-2 with an N-terminal loop but not with a free COOH group of C-terminal Trp.

3.3. Effect of phosphoramidon on ET-2 production in ACHN cells

The ir-patterns of ET-2-related peptides in the supernatant of ACHN cells incubated with phosphoramidon were observed to be similar to those in Fig. 2. Amounts of ET-2(1-21) and big ET-2(22-38) were decreased, and that of big ET-2(1-38) was increased by phosphorami-

don in a dose-dependent manner (Fig. 3). This metalloprotease inhibitor reversed the ratio of ET-2/big ET-2(1-38) at a concentration of 10^{-6} – 10^{-4} M. The amount of ir-big ET-2(1-37), which has been proposed as an intermediate form from the nucleotide sequence of cDNA encoding ET-2, did not change significantly in the presence of phosphoramidon. These results clearly suggest that the intermediate form, big ET-2, is composed of 38 amino acid residues with a C-terminal arginine, and that phosphoramidon inhibits the activity of a putative ECE-2 which produces mature ET-2 from big ET-2(1-38). Although the physiological role of ET-2 has not been thoroughly clarified, it should be noted that ECE-2 possesses the same enzymatic characteristic as ECE-1 with regard to phosphoramidon sensitivity [10]. Recently, as with the physiologically relevant ECE-1 in endothelial cells, a phosphoramidon-sensitive neutral metalloprotease has been proposed [13]. Furthermore, it was suggested that ECE-1 can convert also big ET-3 to ET-3 [14]. It is of great interest to reveal whether or not these enzymes (ECE-1 and ECE-2) have the same characteristics with respect to substrate specificity to big ETs, and whether or not these enzymes are identical. These studies are now in progress.

Acknowledgements: This work was in part supported by grants for Scientific Research on Priority Areas: 'Vascular Endothelium-Smooth Muscle Coupling' from the Ministry of Education, Science and Culture of Japan, from National Cardiovascular Center for Research Institute, Uehara Memorial Foundation and Hamaguchi Biochemical Foundation.

REFERENCES

- [1] Yanagisawa, M., Kurihara, H., Kimura, S., Tomobe, Y., Kobayashi, M., Mitsui, Y., Yazaki, Y., Goto, K. and Masaki, T. (1988) *Nature* 322, 411–415.
- [2] Inoue, A., Yanagisawa, M., Kimura, S., Kasuya, Y., Miyauchi, T., Goto, K. and Masaki, T. (1989) *Proc. Natl. Acad. Sci. USA* 86, 2863–2867.
- [3] Itoh, Y., Yanagisawa, M., Ohkubo, S., Kimura, C., Kosaka, T., Inoue, A., Ishida, N., Mitsui, Y., Onda, H., Fujino, M. and Masaki, T. (1988) *FEBS Lett.* 231, 440–444.
- [4] Doherty, A.M. (1992) *J. Med. Chem.* 35, 1493–1508.
- [5] Ohkubo, S., Ogi, K., Hosoya, M., Matsumoto, H., Suzuki, N., Kimura, C., Onda, H. and Fujino, M. (1990) *FEBS Lett.* 274, 136–140.
- [6] Kosaka, T., Ishibashi, Y., Matsumoto, H., Kubo, K., Kitada, C., Suzuki, N., Yasuhara, T., Onda, H. and Fujino, M. (1991) in: *Peptide Chemistry 1990* (Shimonishi, Y. ed.), pp. 135–138, Protein Research Foundation, Osaka, Japan.
- [7] Sawamura, T., Kimura, S., Shinmi, O., Sugita, Y., Yanagisawa, M. and Masaki, T. (1989) *Biochem. Biophys. Res. Commun.* 162, 1287–1294.
- [8] Kimura, S., Kasuya, Y., Sawamura, T., Shinmi, O., Sugita, Y., Yanagisawa, M., Goto, K. and Masaki, T. (1989) *J. Cardiovasc. Pharmacol.* 13 (Suppl. 5), S5–S8.
- [9] Ikegawa, R., Matsumura, Y., Tsukahara, Y., Takaoka, M. and Morimoto, S. (1990) *Biochem. Biophys. Res. Commun.* 171, 669–675.
- [10] Sawamura, T., Kasuya, Y., Matsushita, Y., Suzuki, N., Shinmi, O., Kishi, N., Sugita, Y., Yanagisawa, M., Goto, K., Masaki, T.

- and Kimura, S. (1991) *Biochem. Biophys. Res. Commun.* 174, 779-784.
- [11] Kosaka, T., Ishibashi, Y., Suzuki, N., Matsumoto, H., Ohkubo, S., Kitada, C., Onda, H. and Fujino, M. (1992) in: *Peptide Chemistry 1991* (Suzuki, A. ed.), pp. 19-24. Protein Research Foundation, Osaka, Japan.
- [12] Shinmi, O., Kimura, S., Yoshizawa, T., Sawamura, T., Uchiyama, Y., Sugita, Y., Kanazawa, I., Yanagisawa, M., Goto, K. and Masaki, T. (1989) *Biochem. Biophys. Res. Commun.* 162, 340-346.
- [13] Okada, K., Miyazaki, Y., Takada, J., Matsuyama, K., Yamaki, T. and Yano, M. (1990) *Biochem. Biophys. Res. Commun.* 171, 1192-1198.
- [14] Matsumura, Y., Tsukahara, Y., Kuninobu, K., Takaoka, M. and Morimoto, S. (1992) *FEBS Lett.* 305, 86-90.